Posts Tagged: "biologic patents"

Key Insights from the PTAB’s Updated Orange Book and Biologic Patent Study

The U.S. Patent and Trademark Office Patent Trial and Appeal Board (PTAB) recently released an update to its Orange Book patent and biologic patent study, examining post-grant petitions filed against Orange Book patents and biologic patents between September 16, 2012, and June 30, 2021. The PTAB classified a petition as challenging an Orange Book-listed patent by comparing the petition’s filing date with data from the U.S. Food and Drug Administration’s (FDA’s) electronic Orange Book indicating when the patent was listed. The PTAB manually identified biologic patents as any patent potentially covering a Purple Book-listed product and any non-Orange Book-listed patent directed to treating a disease or condition.